Advanced Search

Technical Analysis for ZLAB - Zai Lab Limited

Grade Last Price % Change Price Change
grade A 71.72 -1.94% -1.42
ZLAB closed down 1.94 percent on Thursday, June 4, 2020, on 1.37 times normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical ZLAB trend table...
Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Overbought Stochastic Strength 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.94%
Overbought Stochastic Strength -1.94%
Stochastic Reached Overbought Strength -5.63%
Outside Day Range Expansion -5.63%
Overbought Stochastic Strength -5.63%
MACD Bullish Signal Line Cross Bullish -3.09%
Narrow Range Bar Range Contraction -3.09%
Older EOD signals for ZLAB ...
View Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
ZLAB Chart by TradingView
Basic chart:

Profile

Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
Biopharmaceutical Pharmaceutical Industry Natural Sciences Medication

Is ZLAB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
May 28 Zai Lab reports positive data Phase 3 NORA study
May 28 Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer
May 27 Zai Lab Announces Presentations at June Conferences
May 20 The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test
May 19 The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
May 19 Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam- Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections
May 18 Zai lab doses first Chinese patient in late-stage sulbactam-durlobactam trial
May 18 Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections
May 13 China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
May 13 The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
See more ZLAB news...

Indicators

Indicator Value
52 Week High 76.385
52 Week Low 28.0
Average Volume 422,612
200-Day Moving Average 47.43
50-Day Moving Average 63.18
20-Day Moving Average 70.05
10-Day Moving Average 70.40
Average True Range 3.86
ADX 18.49
+DI 27.10
-DI 19.74
Chandelier Exit (Long, 3 ATRs ) 64.82
Chandelier Exit (Short, 3 ATRs ) 72.57
Upper Bollinger Band 77.44
Lower Bollinger Band 62.66
Percent B (%b) 0.61
BandWidth 21.09
MACD Line 2.69
MACD Signal Line 2.67
MACD Histogram 0.0211
Fundamentals Value
Market Cap 3.52 Billion
Num Shares 49.1 Million
EPS -4.94
Price-to-Earnings (P/E) Ratio -14.52
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 76.36
Resistance 3 (R3) 76.55 75.20 75.58
Resistance 2 (R2) 75.20 74.02 75.10 75.32
Resistance 1 (R1) 73.46 73.29 74.33 73.27 75.07
Pivot Point 72.11 72.11 72.55 72.01 72.11
Support 1 (S1) 70.37 70.93 71.24 70.18 68.37
Support 2 (S2) 69.02 70.20 68.92 68.12
Support 3 (S3) 67.28 69.02 67.86
Support 4 (S4) 67.09